SLEEP QUALITY AND HUMAN AMLYOID-BETA KINETICS

睡眠质量和人类淀粉样蛋白-β 动力学

• 批准号: 9934836
• 负责人: Brendan Patrick Lucey
• 金额: $ 16.01万
• 依托单位: WASHINGTON UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2016
• 资助国家: 美国
• 起止时间: 2016-09-15 至 2021-05-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9934836
• 关键词: Abeta synthesis; Administrative Supplement; Affect; Aging; Alzheimer' s Disease; Amyloid beta-Protein; Applications Grants; Cerebrospinal Fluid; Data; Development; Goals; Human; Individual; Kinetics; Neuraxis; Neurodegenerative Disorders; Neurology; Pathogenesis; Pharmacology; Physicians; Production; Proteins; Publishing; Research; Sampling; Scientist; Sleep; Sleep Deprivation; Sleep disturbances; Testing; Universities; Washington; Work; alpha synuclein; cost; hypocretin; improved; interest; novel; parent grant; prevent; professor; programs; receptor; sleep quality; tau Proteins; tau phosphorylation; tau-1; tenure track

Project Summary: Dr. Brendan Lucey, MD is a highly-motivated physician-scientist with a strong interest in sleep, aging, and neurodegenerative disorders such as Alzheimer’s disease. He is an Assistant Professor of Neurology (tenure track) at Washington University and is seeking support from this administrative supplement for research costs to explore novel changes in cerebrospinal fluid (CSF) tau, phosphorylated tau (p-tau), and α-synuclein concentrations with sleep-wake activity and pharmacologic sleep induction via orexin receptor antagonism from suvorexant. Dr. Lucey’s long-term goal is to develop an exciting research program investigating the interrelationships between sleep, aging, and Alzheimer’s disease. Understanding these relationships could drive the development of new treatments to prevent or delay Alzheimer’s disease. This administrative supplement request builds on recently published work and our unpublished preliminary data showing that sleep loss increases concentrations of tau and α-synuclein in cerebrospinal fluid (CSF) and affects the forms of phosphorylated tau (p-tau). Further, this supplement will leverage novel samples collected as part of the parent grant.

项目摘要： 医学博士Brendan Lucey博士是一位积极进取的身体科学家，对睡眠，衰老和 神经退行性疾病，例如阿尔茨海默氏病。他是神经病学的助理教授（任期） 华盛顿大学的轨道），正在寻求这种行政补充的支持 探索脑脊液（CSF）TAU的新变化，磷酸化的TAU（P-TAU）和α-突触核蛋白 睡眠效果活性的浓度和通过Orexin受体拮抗作用的药物诱导诱导 来自Suvorexant。卢西博士的长期目标是制定一个令人兴奋的研究计划，以调查 睡眠，衰老和阿尔茨海默氏病之间的相互关系。了解这些关系可能 推动开发新疗法以预防或延迟阿尔茨海默氏病。这个行政 补充请求基于最近发表的工作以及我们未发表的初步数据，表明睡眠 损失增加了脑脊液（CSF）中Tau和α-突触核蛋白的浓度，并影响 磷酸化的tau（p-tau）。此外，该补充剂将利用作为该样本的一部分收集的新颖样本 父母赠款。

项目成果

Suvorexant Acutely Decreases Tau Phosphorylation and Aβ in the Human CNS.

Suvorexant 急剧降低人类中枢神经系统中的 Tau 磷酸化和 Aβ。

• DOI: 10.1002/ana.26641
• 发表时间: 2023
• 期刊: Annals of neurology
• 影响因子: 11.2
• 作者: Lucey,BrendanP;Liu,Haiyan;Toedebusch,CristinaD;Freund,David;Redrick,Tiara;Chahin,SamirL;Mawuenyega,KwasiG;Bollinger,JamesG;Ovod,Vitaliy;Barthélemy,NicolasR;Bateman,RandallJ
• 通讯作者: Bateman,RandallJ

Age differences in the association between sleep and Alzheimer's disease biomarkers in the EPAD cohort.

• DOI: 10.1002/dad2.12380
• 发表时间: 2022
• 期刊: Alzheimer's & dementia (Amsterdam, Netherlands)